Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California
- None.
- None.
Insights
The recent clinical study results for Spryng™ with OsteoCushion™ Technology present a significant advancement in the treatment of canine osteoarthritis. The use of intra-articular injections to manage joint pain is a well-established practice in veterinary medicine and the introduction of collagen-elastin hydrogel microparticles offers a novel approach. The data indicating a 77.8% improvement in patient conditions, as measured by the Canine Brief Pain Inventory (CBPI) score and hip extension on goniometry, suggests that this technology could lead to enhanced quality of life for affected animals.
From a veterinary perspective, the complete integration of the microparticles with the animal's subsynovial tissue is particularly noteworthy. This could imply a more natural and potentially longer-lasting relief from joint pain compared to traditional treatments. However, it is essential to consider the long-term effects and any potential adverse reactions that may not be apparent in the short-term follow-up of 84 days.
The announcement by PetVivo Holdings, Inc. about the successful completion of the first cohort in a clinical study for their Spryng™ product represents a potential growth catalyst for the company. As the pet care market continues to expand, with pet owners increasingly seeking advanced medical treatments for their companion animals, products like Spryng™ stand to capture a significant market share, particularly if they demonstrate clear advantages over existing therapies.
Investors should monitor the adoption rate of Spryng™ following its commercialization, as well as any partnerships or distribution agreements that PetVivo secures, which could further influence the company's market position and financial performance. Additionally, the company's ability to navigate the regulatory landscape and effectively market the product will be critical factors in its success.
The technology behind Spryng™ with OsteoCushion™ represents an innovative approach within the biomedical device sector, particularly for veterinary applications. The utilization of collagen-elastin hydrogel microparticles to facilitate the restoration of joint mechanics aligns with the broader trend in human and veterinary medicine towards regenerative therapies. This approach not only addresses symptoms but also aims to support the body's natural healing processes.
It is important to scrutinize the scalability of manufacturing these microparticles and maintaining their quality control, as this could impact the ability of PetVivo to meet market demand. Furthermore, given the specificity of the application to the coxofemoral joint, it will be interesting to see if the technology can be adapted for other types of joint diseases or for use in different species, which would significantly broaden the commercial potential of the product.
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that Alexander Amalfitano DVM, of Ethos Veterinary Health and Colorado Animal Specialty & Emergency (CASE) presented at the Veterinary Orthopedic Society (“VOS”) annual conference on the completion of the first cohort of dogs in a clinical study, which examined the benefit and tolerability of an intra-articular injection of collagen-elastin hydrogel microparticles (i.e. Spryng™ with OsteoCuhsion™ Technology) into the coxofemoral joint of dogs with osteoarthritis.
“We were pleased to have Dr. Amalfitano present the Spryng clinical study first cohort results at the VOS annual conference as this data demonstrated initial tolerability and further supports our representations regarding the efficacy of this product as a viable option to assist in the management of lamenes in companion animals,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
Spryng with OsteoCushion Technology is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
The dogs enrolled in this study had been diagnosed with unilateral or bilateral coxofemoral joint osteoarthritis. Nine dogs have completed the study to date. At day 84, 7 of 9 patients (
About Ethos Veterinary Health
Ethos Veterinary Health is a unique and impactful science-focused animal health company with an emphasis on collaboration, evidence-based decision making, a commitment to the veterinary ethos, and cultivation of passion for what we do. The Company operates 18 hospitals across the United States, with over 400 Doctors of Veterinary Medicine, providing advanced medical care for pets. Our approach includes a focus on transformative science, continuous learning and growth for team members and collaboration. For more information, visit www.ethosvet.com.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit https://petvivo.com/ or http://sprynghealth.com.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What is the focus of the clinical study mentioned in the PR?
What is Spryng™ with OsteoCushion™ Technology?
What were the results of the study in terms of CBPI scores?
How many dogs participated in the study?
Where can the abstract of the clinical study be viewed?
